Participation of elderly adults in randomized controlled trials addressing antibiotic treatment of pneumonia

Journal of the American Geriatrics Society

Volumn 63, Issue 2, 2015, Pages 233-243

  Avni, Tomer ^a   Shiver Ofer, Shahaf ^a   Leibovici, Leonard ^a   Tacconelli, Evelina ^b   DeAngelis, Giulia ^c   Cookson, Barry ^d,e   Pagani, Leonardo ^f,g   Paul, Mical ^h,i  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c CATHOLIC UNIVERSITY   (Italy)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f CENTRAL HOSPITAL OF BOLZANO   (Italy)

^g Annecy Genevois Hospital   (France)

^h RAMBAM MEDICAL CENTER   (Israel)

ⁱ TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

elderly; pneumonia; systematic review

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CEFTAROLINE; CEFTOBIPROLE; CEFTRIAXONE; CEFUROXIME; CETHROMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLINDAMYCIN; COLISTIN; DAPTOMYCIN; DORIPENEM; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PANIPENEM PLUS BETAMIPRON; PIPERACILLIN PLUS TAZOBACTAM; ROXITHROMYCIN; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DRUG TREATMENT FAILURE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; META ANALYSIS; MORTALITY; PNEUMONIA; PROSPECTIVE STUDY; SYSTEMATIC REVIEW; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; ADULT; AGE; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; HUMANS; MIDDLE AGED; PATIENT SELECTION; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84923227669     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13250     Document Type: Article

References (64)

1. Leibovici L, Pitlik SD, Konisberger H, et al. Bloodstream infections in patients older than eighty years. Age Ageing 1993; 22: 431-442.
2. Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005; 9: 1-152.
3. Heiat A, Gross CP, Krumholz HM,. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162: 1682-1688.
4. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
5. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.
6. Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: A systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011; 26: 783-790.
7. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA 2007; 297: 1233-1240.
8. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: Results of a population-based study. Clin Infect Dis 2004; 39: 1642-1650.
9. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration, 2011 [on-line]. Available at www.cochrane-handbook.org Accessed April 4, 2014.
10. Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73-81.
11. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: Results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63: 52-61.
12. Betrosian AP, Frantzeskaki F, Xanthaki A, et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56: 432-436.
13. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36: 1089-1096.
14. Dartois N, Castaing N, Gandjini H, et al. Tigecycline 313 Study G. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008; 20 (Suppl 1): 28-35.
15. D'Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49: 4035-4041.
16. Drehobl MA, De Salvo MC, Lewis DE, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128: 2230-2237.
17. English ML, Fredericks CE, Milanesio NA, et al. Cethromycin versus clarithromycin for community-acquired pneumonia: Comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother 2012; 56: 2037-2047.
18. File TM Jr., Low DE, Eckburg PB, et al. FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl 3): 19-32.
19. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-151.
20. Hoffken G, Barth J, Rubinstein E, et al. HAP Study Group. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia. Infection 2007; 35: 414-420.
21. Ito I, Kadowaki S, Tanabe N, et al. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: Comparison with imipenem/cilastatin. Pulm Pharmacol Ther 2010; 23: 403-410.
22. Joshi M, Metzler M, McCarthy M, et al. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006; 100: 1554-1565.
23. Kadowaki M, Demura Y, Mizuno S, et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest 2005; 127: 1276-1282.
24. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16: R218.
25. Kuzman I, Dakovic-Rode O, Oremus M, et al. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: An international, randomized, open-label study. J Chemother 2005; 17: 636-642.
26. Leroy O, Saux P, Bedos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128: 172-183.
27. Lin TY, Lin SM, Chen HC, et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J 2007; 30: 321-332.
28. Low DE, File TM Jr., Eckburg PB, et al. FOCUS 2: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl 3): 33-44.
29. Mokabberi R, Haftbaradaran A, Ravakhah K,. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther 2010; 35: 195-200.
30. Nicholson SC, Welte T, File TM Jr., et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 2012; 39: 240-246.
31. Ott SR, Allewelt M, Lorenz J, et al. German Lung Abscess Study Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36: 23-30.
32. Paladino JA, Eubanks DA, Adelman MH, et al. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia. J Am Geriatr Soc 2007; 55: 651-657.
33. Paris R, Confalonieri M, Dal Negro R, et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: An open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother 2008; 20: 77-86.
34. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46: 1142-1151.
35. Portier H, Brambilla C, Garre M, et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005; 24: 367-376.
36. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: A randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-2126.
37. Reith HB, Rauchschwalbe SK, Mittelkotter U,. Nosocomial pneumonia: Third-group chinolone versus clindamycin/ceftriaxone in modulation of the acute phase reaction and outcome and cost efficacy. Int Surg 2006; 91: 272-275.
38. Schmitt DV, Leitner E, Welte T, et al. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia-a double blind prospective multicentre study. Infection 2006; 34: 127-134.
39. Seki M, Higashiyama Y, Imamura Y, et al. A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia. Intern Med 2009; 48: 49-55.
40. Talaie H, Jabari HR, Shadnia S, et al. Cefepime/clindamycin vs. ceftriaxone/clindamycin for the empiric treatment of poisoned patients with aspiration pneumonia. Acta Biomed 2008; 79: 117-122.
41. Tamm M, Todisco T, Feldman C, et al. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: A prospective, randomised, multicentre study. Clin Microbiol Infect 2007; 13: 162-171.
42. Tanaseanu C, Milutinovic S, Calistru PI, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009; 9: 44.
43. Torres A, Garau J, Arvis P, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: The MOTIV study-a randomized clinical trial. Clin Infect Dis 2008; 46: 1499-1509.
44. Tremolieres F, Mayaud C, Mouton Y, et al. Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults. Pathol Biol (Paris) 2005; 53: 503-510.
45. van Rensburg DJ, Perng RP, Mitha IH, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother 2010; 54: 4098-4106.
46. Welte T, Petermann W, Schurmann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697-1705.
47. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134: 1200-1207.
48. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin Infect Dis 2012; 54: 621-629.
49. Xu S, Xiong S, Xu Y, et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 421-424.
50. Yakovlev SV, Stratchounski LS, Woods GL, et al. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis 2006; 25: 633-641.
51. Yanagihara K, Fukuda Y, Seki M, et al. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Intern Med 2006; 45: 995-999.
52. Zaitsev AA,. Sinopal'nikova AI [The clinical and pharmacoeconomic aspects of gemifloxacin (corrected) use in the patients with extra-hospital pneumonia in stationary conditions]. Voen Med Zh 2007; 328: 44-51.
53. Review Manager (RevMan), Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
54. Leibovici L, Samra Z, Konigsberger H, et al. Long-term survival following bacteremia or fungemia. JAMA 1995; 274: 807-812.
55. Leibovici L,. Long-term consequences of severe infections. Clin Microbiol Infect 2013; 19: 510-512.
56. Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: Still the old man's friend? Arch Intern Med 2003; 163: 317-323.
57. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003; 146: 250-257.
58. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011; 171: 550-556.
59. Falagas ME, Vouloumanou EK, Sgouros K, et al. Patients included in randomised controlled trials do not represent those seen in clinical practice: Focus on antimicrobial agents. Int J Antimicrob Agents 2010; 36: 1-13.
60. Witham MD, McMurdo ME,. How to get older people included in clinical studies. Drugs Aging 2007; 24: 187-196.
61. Pietanza MC, Basch EM, Lash A, et al. Harnessing technology to improve clinical trials: Study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol 2013; 31: 2004-2009.
62. Sugarman J, Califf RM,. Ethics and regulatory complexities for pragmatic clinical trials. JAMA 2014; 311: 2381-2382.
63. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. JAMA 2005; 294: 716-724.
64. Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101: 2239-2246.